Tar­get­ing the tricky PI3K path­way in can­cer, MEI gets $75M to push pro­gram through reg­is­tra­tion study

MEI Phar­ma $MEIP, a small pub­lic com­pa­ny in San Diego, has raised $75 mil­lion in a pri­vate sale of stock to push for­ward its PI3K in­hibitor — a class of drugs with a mixed his­to­ry — to treat a com­mon non-Hodgkin lym­phoma.

The com­pa­ny ac­quired the pro­gram back in 2013 from San Fran­cis­co-based Path­way Ther­a­peu­tics, and has brought the oral drug to clin­i­cal proof-of-con­cept tri­als in both fol­lic­u­lar lym­phoma and in­do­lent lym­phoma and dif­fuse large B-cell lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER